Viking Therapeutics Raises $500M in Upsized Stock and Convertible…

Event summary

Viking Therapeutics priced a $500M offering of 7.86M shares of common stock at $35.00 per share and $225M in 2.00% convertible senior notes due 2032.
The offering size was upsized from the previously announced $200M for both common stock and notes.
Net proceeds estimated at $258.2M from common stock and $218.0M from notes, totaling $476.2M.
Proceeds will fund clinical development of VK2735 and VK3019 programs, along with general corporate purposes.
Underwriters granted a 30-day option to purchase additional shares and notes to cover over-allotments.

The big picture

Viking Therapeutics' $500M capital raise underscores the intense competition in the obesity and metabolic disorder treatment space, where significant funding is required to advance through clinical trials and potential commercialization. The upsized offering suggests strong investor appetite for Viking's pipeline, particularly its lead program VK2735, which is currently in Phase 3 trials. The move also highlights the company's strategic pivot towards securing long-term financing to support its ambitious development goals in a crowded market.

What we're watching

Clinical Milestones: How the pace of VK2735 and VK3019 clinical development will impact the company's ability to meet regulatory and commercialization timelines.
Market Conditions: Whether Viking can sustain investor interest and stock performance given the significant dilution from the equity offering.
Debt Management: The strategic use of convertible notes and the potential impact on Viking's capital structure and future financing options.